Combination Therapy of Cord Blood and G-CSF for Patients With Brain Injury or Neurodegenerative Disorders

A Pilot Study of Combination Therapy of Allogeneic Umbilical Cord Blood and Granulocyte-colony Stimulating Factor for Patients With Brain Injury or Neurodegenerative Disorders

This open label trial is conducted to investigate the efficacy and safety of the combination therapy of allogeneic umbilical cord blood (UCB) and granulocyte-colony stimulating factor (G-CSF) for patients with brain injury or neurodegenerative disorders.

Current treatments for brain injury or neurodegenerative disorders are palliative rather than curative. Preclinical and some clinical studies suggest that UCB and G-CSF can be used as restorative approach for such disorders.

Inclusion Criteria: should be included one of the 4 disorders

• Brain injury: onset duration over 12 months, Age: 19 years or over
• Cerebral palsy: spastic, dyskinetic or ataxic, Age: 19 years or over
• Parkinson's disease: modified Hoehn and Yahr stage 2.5, 3, 4, Age: 30 to 75 years
• ALS: definite of possible ALS, progression during the past 6 months, Age: 19 to 65

Exclusion Criteria:

• Uncontrolled pulmonary, renal dysfunction at enrollment
• Uncontrolled seizure
• Malignant cancer
• Possibility of hypersensitivity to drugs used in this study
• Contraindication to the study intervention or assessment
• Pregnant or breast feeding women
• Non-compliance with the study visits specified in the protocol